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Abstract 22 
OBJECTIVES 23 
The objective of this study was to evaluate the effect of tumor necrosis factor-alpha 24 
inhibitors (TNF-I) on Alzheimer’s disease (AD)-associated pathology. 25 
DESIGN 26 
A literature search of PubMed, Embase, PsychINFO, Web of Science, Scopus and 27 
the Cochrane Library databases for human and animal studies that evaluated the 28 
use of TNF-I was performed on 26th October 2016.  29 
RESULTS 30 
The main outcomes assessed were cognition and behaviour, reduction in brain 31 
tissue mass, presence of plaques and tangles, and synaptic function. Risk of bias 32 
was assessed regarding blinding, statistical model, outcome reporting and other 33 
biases. Sixteen studies were included, 13 of which were animal studies and 3 of 34 
which were human. All animal studies found that treatment with TNF-I leads to an 35 
improvement in cognition and behaviour. None of the studies measured change in 36 
brain tissue mass. The majority of studies documented a beneficial effect in other 37 
areas, including the presence of plaques and tangles and synaptic function. The 38 
amount of data from human studies was limited. Two out of 3 studies concluded 39 
that TNF-I are beneficial in AD patients, with one being an observational study 40 
and the latter being a small pilot study, with a high risk of bias. 41 
CONCLUSION 42 
It was concluded that a large scale randomised controlled trial assessing the 43 
effectiveness of TNF-I on humans is warranted. 44 
  45 
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INTRODUCTION 46 
 47 
The role of neuroinflammation in AD 48 
Almost three decades ago, McGeer and colleagues noted the association between 49 
anti-inflammatory drugs and reduced risk for developing Alzheimer's disease (AD) 50 
(McGeer, Rogers, McGeer & Sibley,1990). Subsequent studies led to identification 51 
of large numbers of immune cells found in the proximity of senile plaques and 52 
neurofibrillary tangles, the histological lesions characteristic for AD (Eldik et al. 53 
2016).  54 
 55 
The presence of A deposits in the brain can lead to the activation of an immune 56 
response and the recruitment of glial cells. In response to toxic A deposits, 57 
microglia undergo morphological and functional changes to neutralise them 58 
(Olabarria, Noristani, Verkhratsky & Rodriguez, 2010). As glial cells are unable to 59 
remove the debris, their function becomes altered in a way that they actively 60 
contribute to inflammation (Bronzuoli et al. 2016).  61 
 62 
Recent identification of genes associated with susceptibility to Alzheimer’s disease 63 
provided basis for establishing the first non-descriptive link between inflammatory 64 
processes and development of AD pathology (Heppner, Ransohoff, Becher, 2015). 65 
Mutations in genes coding for triggering receptor expressed on myeloid cells 2 66 
(TREM2) and myeloid cell surface antigen CD33 lead to a significantly increased 67 
risk of AD through impaired induction of inflammatory processes (Bradshaw et al., 68 
2013; Jonsson et al. 2013)   69 
 70 
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Furthermore, studies on transgenic mice demonstrated that experimental induction 71 
of neuroinflammation initiated by administration of lipopolysaccharide (LPS) leads 72 
to an increase in amyloid beta deposition (Sheng et al., 2003; Lee et al., 2008). 73 
 74 
It has been demonstrated that TNF- can potentiate the astroglial response, driving 75 
the neuroinflammatory process (Hensley, 2010). TNF- along with interleukin-1 76 
and interferon- myloid precursor protein (APP) 77 
by gamma-secretase via activation of the mitogen activated protein kinases 78 
(MAPK) pathway (Liao et al. 2004). TNF- - 79 
signalling that results in an increase in the production of amyloid beta (A (Chen et 80 
al. 2012). 81 
 82 
Thus, an increasing amount of evidence suggests that modulation of inflammation 83 
through targeting TNF- may be a potential therapeutic strategy for AD. 84 
 85 
TNF- αI 86 
 87 
TNF-alpha is a powerful cytokine involved in the chronic inflammatory response 88 
(Akiyama, et al., 2000). Tarkowski et al. (2003) revealed a 25-fold difference in the 89 
levels of TNF-alpha in patients with AD compared to controls. Increasing evidence 90 
for the role of TNF-I in alleviating AD-related pathology prompted the first 91 
administration of Etanercept for primary progressive aphasia (Tobinick, 2008). 92 
Significant cognitive benefits were observed following the first dose of treatment. 93 
The results of this study suggested that TNF-alpha may play a pivotal role in the 94 
pathology of AD and exemplified its potential as a new therapeutic target. 95 
 96 
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 97 
Aims and objectives of the current review 98 
Previous non-systematic reviews have reported on the mechanism of action of 99 
TNF- and the possible benefits of TNF-alpha downregulation in AD (Cheng et al., 100 
2014; McCaulley and Grush, 2015). The previous reviews explored the effects of 101 
Etanercept, Infliximab, Pentoxifylline and Thalidomide on AD pathology, with little 102 
critical appraisal. To the authors' knowledge, no systematic review of studies 103 
investigating the role of TNF-alpha in the pathogenesis of AD has been published. 104 
Thus, the objective of the current review was to conduct a systematic and critical 105 
analysis of the available evidence from both animal and human studies to establish 106 
whether targeting TNF-alpha is a feasible strategy for the treatment of AD and 107 
whether this class of drugs has a potential to be tested in a large-scale human trial. 108 
Four main categories of outcomes were focused on: cognition and behaviour, 109 
reduction in brain tissue mass, presence of plaques and tangles, and synaptic 110 
function. Neuropathological features were the main focus of treatment as they are 111 
the main trigger of the chronic inflammatory response seen in these individuals 112 
(Zotova, Nicoll, Kalaria, Holmes, & Boche, 2010). It was beyond the scope of this 113 
review to investigate the effect of TNF-I on inflammation markers. 114 
 115 
METHODS  116 
 117 
Literature search 118 
Six databases (PubMed, Embase, PsychINFO, Web of Science, Scopus and the 119 
Cochrane Library) were searched on 26th of October 2016 using the following 120 
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search terms: (etanercept OR infliximab OR adalimumab OR certolizumab OR 121 
golimumab OR pentoxiflylline OR “tumor necrosis factor inhibitor” OR “TNF 122 
inhibitor” OR “tumour necrosis factor inhibitor” OR “tumour necrosis factor-alpha 123 
inhibitor” OR “TNF-alpha inhibitor”) AND (dement* OR alzheim* OR “cognitive 124 
decline” OR “cognitive dysfunction” OR “cognitive impairment” OR “cognitive deficit” 125 
OR “memory decline” OR “memory dysfunction” OR “memory impairment” OR 126 
“memory deficit” OR “neuropsychological test”). Etanercept, infliximab, 127 
adalimumab, certolizumab, golimumab, pentoxiflylline are TNF-I currently used for 128 
the treatment of rheumatoid arthritis (RA).  129 
 130 
Inclusion/exclusion criteria  131 
Studies were included if they met the following criteria: (1) published in a peer-132 
reviewed journal without any language restrictions; (2) report original work; (3) 133 
conducted on animal subjects or human participants; (4) the intervention had to 134 
include an administration of a TNF-I or a genetic intervention leading to ablation of 135 
the TNF receptor (TNFR); (5) animal studies had to include transgenic or non-136 
transgenic models of AD; and (6) human participants had to be diagnosed with AD. 137 
Conference proceedings, case studies, research protocols and unpublished 138 
dissertations or theses were excluded. In addition, studies on cell cultures were 139 
excluded. 140 
 141 
Screening and data extraction 142 
Studies were blindly and independently screened by two raters (JE and GR). 143 
Initially, titles and abstracts were screened and then full-text articles were retrieved 144 
for all potentially relevant studies. Discrepancies were resolved through discussion 145 
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with an independent reviewer (RG). Two raters (JE and GR) blindly and 146 
independently extracted data on study characteristics, methodology of the study 147 
and outcomes with respect to neuropsychiatric and neurohistopathological findings 148 
(as outlined in the Introduction). Again, any discrepancies were resolved through 149 
discussion with an independent reviewer (RG). 150 
 151 
Quality assessment of methodology 152 
The methodological quality of studies was assessed to identify potential biases, 153 
confounding factors and any errors that could affect the interpretation of the results. 154 
There is no agreed instrument for assessing methodology and risk of bias in animal 155 
studies (Krauth, Woodruff, & Bero, 2013). Consequently, a quality assessment tool 156 
was developed for the purposes of this review based on criteria proposed by 157 
Krauth, Woodruff & Bero (2013). Some of the criteria were unique to animal studies 158 
and allowed for the measurement of bias, reporting and methodological issues. The 159 
EPHPP Quality Assessment Tool (Effective Public Health Practice Project, 2009) 160 
was used for human studies as it can be applied to all study designs. The quality of 161 
studies was evaluated in the following categories: selection bias, study design, 162 
confounder, blinding, data collection methods, withdrawals and drop-outs, 163 
intervention integrity and statistical analysis (see Appendix E). The methodological 164 
quality of included studies was assessed by two blind, independent raters (JE and 165 
GR), with any discrepancies in ratings being resolved through discussion with an 166 
independent reviewer (RG).  167 
 168 
 169 
 170 
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 171 
RESULTS  172 
 173 
Identification and Characteristics of Included Studies 174 
As shown in Figure 1, 1038 potentially relevant studies were initially identified, from 175 
which 477 duplicates were removed, yielding a total of 561 potentially relevant 176 
studies. After initial screening of titles and abstracts, 526 studies were excluded. 177 
This resulted in the extraction of 35 full-text articles, 16 of which met the inclusion 178 
criteria. 179 
 180 
Study characteristics 181 
Animal studies 182 
Thirteen animal studies assessing the potential use of TNF-I in the treatment of 183 
AD were identified (see Appendix A for detailed characteristics) (Cavanagh, et al., 184 
2016) (Detrait, Danis, Lamberty, & Foerch, 2014) (Gabbita, et al., 2012) (He, 185 
Cheng, Staufenbiel, Li, & Shen, 2012) (Kim, et al., 2016) (McAlpine, et al., 2009) 186 
(Medeiros, et al., 2007) (Medeiros, et al., 2010) (Montgomery, et al., 2011) 187 
(Roerink, et al., 2015) (Russo, et al., 2012) (Shi, et al., 2011) (Tweedie, et al., 188 
2012). The studies were very heterogenous. Transgenic mice were subjects in 9 189 
out of 13 studies (Cavanagh, et al., 2016; Gabbita, et al., 2012; He, Cheng, 190 
Staufenbiel, Li, & Shen, 2012; McAlpine, et al., 2009; Medeiros, et al., 2007; 191 
Medeiros, et al., 2010; Montgomery, et al., 2011; Shi, et al., 2011; Tweedie, et al., 192 
2012).Three studies used non-transgenic mice (Detrait et al., 2014; Kim, et al., 193 
2016; Russo, et al., 2012) and one was conducted on rats as well as transgenic 194 
mice (Tweedie, et al., 2012). The most common transgenic model of AD was 3xTg-195 
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AD type and was used in four studies (Gabbita, et al., 2012; McAlpine, et al., 2009; 196 
Montgomery, et al., 2011; Tweedie, et al., 2012). A injections were used in five 197 
studies to induce similar changes to those seen in AD (Detrait et al., 2014) (Kim, et 198 
al., 2016; Medeiros, et al., 2007; Medeiros, et al., 2010; Russo, et al., 2012). The 199 
number of animals was unreported in the majority of studies. Only three of them 200 
stated this number, which ranged from nine to twenty-two (Roerink, et al., 2015; 201 
Shi, et al., 2011; Tweedie, et al., 2012). Consequently, it was not possible to 202 
calculate effect sizes. The most frequently used type of TNF-I was 3,6’-203 
dithiothalidomide, administered in three studies (Gabbita, et al., 2012; Russo, et al., 204 
2012; Tweedie, et al., 2012). The methods of drug delivery included intraperitoneal, 205 
intracerebroventricular, subcutaneous injections and stereotactic infusion. 206 
Peripheral administration via an intraperitoneal injection was the most common 207 
intervention, used in seven studies (Gabbita, et al., 2012; He et al., 2012; McAlpine, 208 
et al., 2009; Medeiros, et al., 2010; Russo, et al., 2012; Shi, et al., 2011; Tweedie, 209 
et al., 2012). The length of treatment ranged from one to 90 days. One paper did 210 
not report the duration of intervention (Montgomery, et al., 2011).  211 
 212 
Human studies 213 
Three studies on humans were identified (see Appendix B for detailed 214 
characteristics and Appendix C for inclusion/exclusion criteria), which were 215 
heterogeneous in a number of areas. The types of study design included a 216 
randomised double-blind controlled trial (Butchart, et al., 2015), nested case-control 217 
study (Chou, Kane, Ghimire, Gautam, & Gui, 2016) and a prospective, single 218 
centre, open-label pilot study (Tobinick et al., 2006). The number of participants 219 
ranged from 15 to 325. With respect to diagnosis, standard clinical criteria were 220 
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used to diagnose AD in two studies (Butchart, et al., 2015; Tobinick et al., 2006) 221 
and both RA and AD in one study (Chou et al., 2016). Where reported, the age of 222 
participants ranged from 18 to 94 years, with the mean age ranging from 72.4 to 223 
76.7 years (Butchart, et al., 2015; Tobinick et al., 2006). The mean Mini–Mental 224 
State Examination (MMSE) score in two out of three interventional studies that 225 
provided these data was similar: 18.2 and 20.3 (Butchart, et al., 2015; Tobinick et 226 
al., 2006). All studies recruited participants of both sexes: the mean percentage of 227 
female participants was 60%. 228 
 229 
Administration of etanercept was the primary intervention in two out of three studies 230 
(Tobinick et al., 2006; Butchart, et al., 2015). Chou et al. (2016) carried out an 231 
observational study that aimed to determine the relative risk of AD in a cohort of 232 
patients receiving TNF-I for RA in comparison with RA individuals without AD. In 233 
the study by Tobinick et al. (2006), etanercept was administered perispinally, in 234 
contrast to the study by Butchart et al. (2015) which involved a subcutaneous 235 
injection. Butchart et al. (2005) failed to report the details of the process of 236 
participant recruitment. The study carried out by Tobinick et al. (2006) recruited 237 
individuals from the community. Chou et al. (2016) performed a search in the Verisk 238 
Health claims database to obtain a cohort of participants with a diagnosis of AD and 239 
RA and RA only as a control. Patients received treatment for 6 months in the 240 
studies carried out by Tobinick et al. (2006) and Butchart et al. (2005). The length 241 
of treatment could not be determined in the study by Chou et al. (2016) due to its 242 
retrospective study design. 243 
 244 
 245 
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 246 
Quality Assessment 247 
Animal Studies 248 
Ratings of the methodological quality of included animal studies are provided in 249 
Appendix D. Only two studies reported that treatment was allocated randomly (Shi, 250 
et al., 2011; Detrait et al., 2014). These studies also explicitly stated that the 251 
investigator involved in the experiment was blinded to the intervention (Shi, et al., 252 
2011) (Detrait et al., 2014). Blinding was only partially described in three studies 253 
(He et al., 2012) (Kim, et al., 2016) (Russo, et al., 2012). None of the studies 254 
provided information on how the number of study animals was calculated. The 255 
requirement for compliance with the Animal Welfare Act was met by all studies. 256 
Four studies declared no financial conflict of interest (Cavanagh, et al., 2016) 257 
(Detrait et al., 2014) (Roerink, et al., 2015) (Shi, et al., 2011). The statistical 258 
methods used to analyse the results obtained were partially adequate (Cavanagh, 259 
et al., 2016) (Kim, et al., 2016) (Medeiros, et al., 2007) (Montgomery, et al., 2011) 260 
(Shi, et al., 2011) (Russo, et al., 2012) or fully explained (Detrait et al., 2014) 261 
(Gabbita, et al., 2012) (He et al., 2012) (McAlpine, et al., 2009) (Tweedie, et al., 262 
2012) (Medeiros, et al., 2010) in all studies, except one (Roerink, et al., 2015). The 263 
presence of any comorbidities in test animals was not reported in any of the 264 
studies. All of the studies provided partial information on the characteristics of the 265 
animal used, such as species, strain, genetic background, supplier, sex and weight. 266 
None of the studies, however, reported enough detail to fully meet this criterion. No 267 
mention was made in any of the studies as to whether the dose-response pattern 268 
was suitable to address the hypothesis. All of the included studies failed to report if 269 
any animals had been withdrawn from the experiment before its completion. The 270 
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time window for assessing the outcome of the experiments was rated as adequate 271 
in twelve out of thirteen studies (Cavanagh, et al., 2016) (Detrait et al., 2014) 272 
(Gabbita, et al., 2012) (He et al., 2012) (Kim, et al., 2016) (McAlpine, et al., 2009) 273 
(Medeiros, et al., 2007) (Medeiros, et al., 2010) (Roerink, et al., 2015) (Russo, et 274 
al., 2012) (Tweedie, et al., 2012). 275 
 276 
Human Studies 277 
Ratings of the quality of human studies are listed in Appendix E. The participants in 278 
the study by Butchart et al. (2015) were likely to be representative of the target 279 
population. There was a partial risk of selection bias in the study by Chou et al. 280 
(2016) and Tobinick et al. (2006). Two out of three studies were randomized and 281 
the study design was rated as adequate (Butchart, et al., 2015) (Tobinick et al., 282 
2006). The study by Chou et al. (2016) was a retrospective case control analysis 283 
(Chou et al., 2016). The confounding factors were well-controlled in one study 284 
(Butchart, et al., 2015). It is unclear whether participants of the two remaining 285 
studies were exposed to any factors that may have affected the results (Chou et al., 286 
2016) (Tobinick et al., 2006). Blinding was adequate in only one study (Butchart, et 287 
al., 2015) and partially adequate in the two remaining ones (Chou et al., 2016) 288 
(Tobinick et al., 2006). The data collection methods were valid and reliable in all 289 
studies. Any withdrawals or drop-outs were appropriately reported in two studies 290 
(Butchart, et al., 2015) (Tobinick et al., 2006). The integrity of the intervention was 291 
adequate in the study by Chou et al. (2016) and partially adequate in Butchart et al. 292 
(2015) The study by Tobinick et al. (2006) was a pilot study hence the intervention 293 
integrity was rated as inadequate.  294 
 295 
 13 
Results of included studies 296 
The findings in each subcategory are discussed below (see Appendix F for a 297 
summary of the key outcomes). 298 
 299 
Cognition and behaviour 300 
In all studies that assessed changes in cognition and behaviour, the effect of TNF-301 
I was beneficial. Cavanagh et al. (2016) showed that an increase in hippocampus-302 
dependent synaptic function, an early pathological sign of AD, can be reversed by 303 
an administration of XPro1595. 304 
 305 
A-associated cognitive deficits in mice were also diminished by a subcutaneous 306 
injection of the TNF receptor 2 fused to a fragment crystallisable (Fc) domain used 307 
clinically for the treatment of RA (Detrait et al., 2014). The animals showed a dose-308 
related response in alternation percentage in the Y-maze, with a complete reversal of 309 
cognitive deficits at 30mg/kg (Detrait et al., 2014).  310 
 311 
Changes in exploration of the radial arm on administration of 3,6’-dithiothalidomide, 312 
but not thalidomide, in 3xTg mice were observed in one experiment (Gabbita, et al., 313 
2012). Consistent with previous findings, 3,6’-dithiothalidomide was found to 314 
ameliorate the cognitive deficits induced by an injection of A1-42.  315 
 316 
Kim et al. (2016) injected mice with A1-42 and performed a novel object recognition 317 
test after administration of Infliximab. Results showed that the drug counteracted the 318 
A1-42 memory impairment (Kim, et al., 2016). Tweedie et al. (2012) provided further 319 
evidence for the beneficial effect of 3,6’-dithiothalidomide-treated on cognition and 320 
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demonstrated that it is capable of decreasing levels of phosphorylated tau (Tweedie, 321 
et al., 2012). 322 
 323 
Medeiros et al. (2007) investigated the effect of A1-40 injection on TNFR1 knock-out 324 
and iNOS-knock out mice. It was found that genetic and pharmacological inhibition of 325 
these signaling pathways ameliorated learning and memory deficits in AD-mice 326 
models.  327 
Another study revealed that treatment with a COX-2 inhibitor and AbTNF-alpha in 328 
57BI/6 and TNFR1 knockout mice prevented cognitive decline and led to an 329 
improvement in spatial learning deficits (Medeiros, et al., 2010). 330 
 331 
Reduction in brain tissue mass 332 
None of the studies investigated the effect of TNF-I on brain tissue mass. 333 
 334 
Presence of plaques and tangles 335 
Although the majority of included animal studies reported a reduction in the quantity 336 
of neuropathological features, the results were not fully consistent. Gabbita et al. 337 
(2012) showed no differences in the number of 6E10 positively stained cells in the 338 
hippocampus on thalidomide and 3,6’-dithiothalidomide administration (Gabbita, et 339 
al., 2012). Contradicting results were obtained from a different study, which not only 340 
showed a decrease in the number of 6E10+ cells, but also in the total levels of A 341 
(He et al., 2012). Western blotting performed on tissue samples from both 342 
thalidomide-treated and non-treated mice demonstrated a decrease in the activity of 343 
a  secretase, BACE1 (He et al., 2012) (O'Brien & Wong, 2011). 344 
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 345 
McAlpine et al. (2009) investigated the effect of short- and long-term inhibition of 346 
TNF-alpha signaling on the amyloid plaque burden in lipopolysaccharide (LPS-347 
challenged mice. The first method involved inhibition of TNF signaling for a period of 348 
one month using XENP345, while the lentivirus-based approach blocked the pathway 349 
for a period of at least one year. A significant decrease in the number of 6E10-350 
immunoreactive cells in the hippocampus of XENP345-treated and the lentivirus-351 
infected mice was seen (McAlpine, et al., 2009). 352 
 353 
A semi-quantitative analysis of brain samples from APP/PS1 mutants following an 354 
injection with Infliximab demonstrated a 40-60% decrease in A deposits as well as a 355 
reduction in levels of hyperphosphorylated tau (Shi, et al., 2011).  356 
 357 
Synaptic function 358 
Despite increasing evidence for synaptic dysfunction in AD, only three out of thirteen 359 
studies investigated this process. Cavanagh et al. (2016) assessed the effect of 360 
XPro1595 on synaptic deficits in transgenic mice. An overall enhancement of 361 
synaptic function in pre-plaque animals was observed. A study on 3xTg-ADxTNG-362 
RI/RII knock-out mice confirmed the findings that synaptic dysfunction appears 363 
before the onset of pathology in animal models of AD (Cavanagh et al. 2016). 364 
Electrophysiological properties of tissue samples from mice injected with A 365 
demonstrated that A1-42 hinders the process of long-term depression. This effect 366 
was reversed following the administration of Infliximab (Kim et al., 2016). 367 
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Human Studies 368 
The included human studies investigating the link between TNF-I and the risk of AD 369 
only assessed changes in cognition and behaviour (see Appendix G for a summary 370 
of the key outcomes). Butchart et al. (2015) conducted a double-blind study with 371 
patients with mild to moderate AD to determine the tolerability and safety of 372 
etanercept. There were 20 participants in the etanercept group, and 21 in the 373 
placebo group. Adverse events were less common in the etanercept group (42 374 
events) compared with the control group (55 events); however, this difference was 375 
not statistically significant. The nested case-control analysis performed by Chou et al. 376 
found a negative association between the use of etanercept and the risk of AD. 377 
Although this study did not examine the effect of TNF-I on any of this review’s main 378 
outcomes, it was included as it provides additional evidence for the use of TNF-I in 379 
AD. Tobinick et al. (2006) conducted a prospective, single-centre pilot study that 380 
recruited 15 patients within the residing community. The participants were 381 
administered a weekly dose of Etanercept for six months. The results of the study 382 
demonstrated a significant difference between the etanercept and placebo group in 383 
MMSE, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and 384 
Severe Impairment Battery (SIB) over six months (Tobinick et al., 2006). 385 
 386 
DISCUSSION 387 
 388 
The main findings of this systematic review will be summarized below and compared 389 
with the findings of previous reviews. The clinical and research implications and 390 
strengths and limitations of the current review will also be discussed.  391 
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Previous findings 392 
Evidence from animal studies presented in this review supports the mechanism 393 
underlying the use of TNF-I in ameliorating AD pathology, as described by Cheng, 394 
Shen, & Li, (2014). A wider range of TNF-I were explored in the current systematic 395 
review in comparison with the aforementioned narrative review (Cheng et al., 2014), 396 
and so the potential of this class of drugs might have been previously 397 
underestimated. Consistent with the findings of McCaulley and Grush (2015), TNF-I 398 
were found to have a beneficial effect in patients with AD in the current review. 399 
However, a more detailed analysis conducted in the current review compared to the 400 
previous narrative review (McCaulley & Grush, 2015) revealed many flaws in the 401 
quality and significance of existing data. 402 
 403 
Research implications 404 
The role of the TNF signaling pathway has been a subject of many other studies, 405 
some of which may have therapeutic implications for AD patients. The evidence 406 
provided by Medeiros et al. (2007) suggested that TNF-alpha might promote the 407 
expression of inducible nitric oxide synthase (iNOS) in the CNS, leading to a more 408 
rapid progression of the pathology. Hence, modulating the levels of TNF-alpha in 409 
parallel with iNOS could be a potential therapeutic strategy for AD (Medeiros et al., 410 
2007). 411 
 412 
The open-label pilot study conducted by Tobinick et al. (2006) included the 413 
administration of Etanercept, in addition to the standard medication recommended in 414 
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the treatment of AD. For this reason, the contribution of these drugs to the 415 
improvement seen in the participants of this study cannot be determined. Future 416 
studies should focus on separating the effect of TNF-I from the already established 417 
treatment to determine their true effectiveness. The analysis of the methodological 418 
quality of the study revealed a possible conflict of financial interest (Tobinick et al., 419 
2006). Thus, the conclusions from this study may be subject to bias and so the study 420 
should be replicated. 421 
 422 
The results obtained from Roerink et al. (2015) contradicted the study by Tobinick et 423 
al. (2006). The perispinal injection of radiolabeled cetuximab, entanercept and 424 
anakinra showed that in eight out of nine rats the compounds were not able to cross 425 
the brain-blood barrier (BBB) (Roerink, et al., 2015). This finding suggests that high-426 
molecular weight compounds may not be effective in the treatment of AD due to their 427 
low penetrability. The importance of molecular weight on the observable therapeutic 428 
effects has also been discussed by McCaulley and Grush (2015). Small molecular 429 
TNF-alpha modulators such as thalidomide and 3,6’-dithiothalidomide should be 430 
tested. 431 
 432 
In the study conducted by Chou et al. (2016) the analysis period ranged from 2000-433 
2007, with the minimum age of participants being 18 years. Hence, the drug regime 434 
might have changed substantially over this period. A case-control analysis, including 435 
more recent data should be conducted. 436 
 437 
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The route of drug administration may also play an important role in achieving the 438 
most beneficial outcome. While Butchart el al (2015) chose to administer etanercept 439 
subcutaneously, Tobinick et al. (2005) injected the drug perispinally. Future research 440 
should focus on comparing the two methods. 441 
 442 
The effectiveness of pentoxifylline on slowing down the progress of mental 443 
deterioration in patients with a diagnosis of multi-infarct dementia has also been 444 
investigated (European Pentoxifylline Multi-Infarct Dementia [EPMID] Study Group, 445 
1996). A significant improvement on the Gottfries-Bråne-Steen (GBS) scale was 446 
seen. However, the study reported no decline in MMSE score over a 9-month period, 447 
which might imply that patients diagnosed with AD did not participate in the trial or 448 
that the treatment period was too short. Investigating the effect of Pentoxifylline on 449 
patients with a diagnosis of AD would be desirable. 450 
 451 
Butchart et al. (2015) used six neuropsychometric tests to assess the effect of 452 
subcutaneous Etanercept on secondary clinical outcomes. After correcting for 453 
multiple comparisons, no statistically significant differences in scores on the 454 
neuropsychometric tests were found (Butchart, et al., 2015). Based on these results, 455 
it may be suggested that a TNF-I with different pharmacokinetic properties should 456 
be tested in a clinical trial. Evidence from a study of the effect of thalidomide, 457 
etanercept and infliximab on rat models of dementia showed that the thalidomide-458 
treated group performed best in the Morris water maze test (Elcioglu, et al., 2015). 459 
This finding suggests that future research should investigate the effect of thalidomide 460 
on AD pathology. 461 
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 462 
Currently, only limited evidence of the effect of TNF-I on synaptic function is 463 
available and more research in this area is required. None of the studies measured 464 
reduction in brain tissue mass. Given that this is a good indication of disease 465 
severity, future research should take this into consideration. 466 
 467 
Clinical implications 468 
It has been shown that an increase in synaptic function of glutamatergic neurons 469 
occurs before the development of AD pathology, subsequently leading to deleterious 470 
effects on cognition (Dickerson, et al., 2005). The administration of an TNF-I in the 471 
study by Cavanagh et al. (2016) diminished the observed abnormalities. For this 472 
reason, treatment with TNF-I could prove beneficial for patients in the initial stages 473 
of the disease.  474 
 475 
Strengths and limitations 476 
The main strengths of the review was that a broad range of studies were searched 477 
across six databases. Furthermore, extracting the information on research design 478 
and analytical methods enabled classification of the quality and impact of studies. 479 
The main limitations of the review were that it was not possible to statistically 480 
synthesize the results of the included studies as the sample size was not stated in 481 
the vast majority of them. The conclusions are therefore only descriptive and lack 482 
quantitative synthesis. Non-peer reviewed studies including posters and dissertations 483 
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were also excluded. Furthermore, grey literature sources were not included in the 484 
initial screening, which may have resulted in publication bias. 485 
 486 
Conclusion 487 
Despite high heterogeneity in interventions assessed and outcomes measured, it can 488 
be concluded that TNF-I have a beneficial effect on cognition and behaviour based 489 
on evidence from animal studies of AD models. All studies, except one, showed that 490 
the administration of TNF-I ameliorates AD-related pathology. Results from an 491 
observational study and a pilot study suggested that treatment with TNF-I may be 492 
beneficial for patients with AD. However, due to the conflict of interest in one of the 493 
studies and small sample size, caution should be expressed when interpreting the 494 
results. Chou et al. (2016) showed that out of all therapeutic drugs for RA, only 495 
treatment with TNF-I correlated with a decreased risk of AD. Taken together, there 496 
is sufficient data to suggest that a large scale randomized controlled trial assessing 497 
the effectiveness of TNF-I should be conducted on humans.  498 
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 734 
Authors Population Model 
Number of 
subject 
animals 
Drug Dose 
Method of drug 
delivery 
Length of 
treatment 
Cavanagh  
et al. (2016) 
Transgenic 
mice 
TgCRND8 unreported XPro1595 10mg/kg subcutaneous 28 days 
Detrait et al. 
(2014) 
NTG 
injected 
with Aβ25-35 
or scAβ25-
35 
unreported Etanercept 30mg/kg subcutaneous 
once a day on 
days 2, 4 and 6 
Gabbita et 
al. (2012) 
Transgenic 
mice 
3xTgAD unreported 
3,6-
dithiothalidomide 
and thalidomide 
50mg/kg intraperitoneal 
daily for 70 
days 
He et al. 
(2013) 
Transgenic 
mice 
APP23 
Insufficient 
detail 
Thalidomide 100mg/kg intraperitoneal 
daily for 90 
days or 3 days 
Kim et al. 
(2016) 
NTG 
injected 
with Aβ1-
42 
unreported Infliximab 2μg/3μl intracerebroventricular 
once in 24 
hours 
McAlpine et 
al. (2009) 
Transgenic 
mice 
3xTgAD unreported 
DN-TNF 
XENP345 or 
DN-TNF 
0.1mg/kg/day intraperitoneal 
twice weekly 
for 28 days 
Medeiros et 
al. (2007) 
Transgenic 
mice 
TNFR1-KO 
and 
injected 
with Aβ1-40 
unreported 
AbTNF-α, 
aminoguanidine, 
JNK or 
pyrrolidine 
dithiocarbonate 
AbTNF-α - 10ηg, 
aminoguanidine 
- 100mg/kg, JNK 
- 50mg/kg, or 
pyrrolidine 
dithiocarbonate - 
100mg/kg 
intracerebroventricular 8 days 
Medeiros et 
al. (2010) 
Transgenic 
mice 
Injected 
with Aβ1-40 
unreported 
AbTNF and    
COX-2 inhibitor 
NS398 
1 mg/kg of 
NS398 and 
10ng/mice of 
AbTNF-alpha 
intraperitoneal 
twice a day for 
7 days 
Montgomery 
et al. (2011) 
Transgenic 
mice 
3xTg-
ADxTNF-
RI/RII KO 
unreported rAAV2 2μl stereotactic infusion unknown 
Roerink et 
al. (2015) 
NTG Rats 9 
cetuximab, 
etanercept 
anakinra 
cetuximab - 146 
kDetanercept - 
51 kDa,  
anakinra - 17 
kDa 
perispinal injection one injection 
Russo et al. 
(2012) 
NTG 
injected 
with Aβ1-42 
unreported 
3,6-
dithiothalidomide 
56mg/kg intraperitoneal 
daily for 14 
days to explore 
hippocampal 
progenitor cell 
proliferation 
and daily for 5 
weeks to look 
at progenitor 
cell survival 
and generation 
of newly 
derived 
neurons 
Shi et al. 
(2011) 
Transgenic 
mice 
APP/PS1 20 Infliximab 150μl intraperitoneal 
daily for three 
days 
Tweedie et 
al. (2012) 
Transgenic 
mice and 
Rats 
3xTg-AD 
and LPS 
challenged 
rats 
22 
3,6-
dithiothalidomide 
LPS: 56mg/kg 
3xTg-AD: 
42mg/kg 
intraperitoneal 
LPS: 14 days 
3xTg-AD: daily 
for 42 days 
Note: A = amyloid peptide; AbTNF-α= anti-TNF-α antibody; APP23= APPswedish mutation transgenic;  COX-2= Cyclooxygenase 2; 735 
DN-TNF= dominant-negative tumor necrosis factor; JNK= c-Jun N-terminal kinase; kDa= kilodaltons; LPS=lipopolysaccharide; NTG= 736 
non-transgenic mice; rAAV2=recombinant adeno-associated virus serotype-2 (rAAV2); scAb = scrambled amyloid peptide; TNFR1-KO= 737 
TNF receptor 1-knockout; TNFR2:Fc= TNF receptor 2 fused to a Fc domain 738 
 739 
  740 
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Appendix B: Key characteristics of human studies. 741 
 742 
Note: AD= Alzheimer’s disease; Anti-CD20= a new generation monoclonal antibody; DSM-IV= Diagnostic and Statistical Manual of 743 
Mental Disorders, 4th Edition; ICD-9= International Statistical Classification of Diseases and Related Health Problems, Ninth Revision; 744 
MMSE= The Mini–Mental State Examination; NINCDS= National Institute of Neurological and Communicative Disorders and Stroke; 745 
NINCDS-ADRDA= National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related 746 
Disorders Association; RA= rheumatoid arthritis; RCT= Randomised-controlled trial; Tx= treatment 747 
 748 
  749 
 
Study 
design 
Number of 
participants 
Diagnosis 
Mean 
age 
[years]
, age 
range 
Mean MMSE 
Sex (% 
male) 
Tx 
 
 
Method of 
administration 
Setting Dose 
Length 
of Tx 
[months] 
Butchart 
et al. 
(2015) 
double-
blind 
RCT 
67 
screened, 
41 
recruited 
and 33 
completed 
(N=18 in 
etanercept 
group, 
N=15 in 
placebo) 
Probable 
AD defined 
by the 
NINCDS 
criteria 
72.4, 
NK 
20.0 for 
Etanercept, 
20.3 for 
placebo 
61 Etanercept 
 
 
 
 
 
subcutaneous 
Single-
centre 
50mg 
once 
weekly 
6 
Chou et 
al. (2016) 
nested-
case 
control 
Identified=8
,500,454 
participants 
with 
RA=41,109 
participants 
with 
AD=9253 
total 
number 
with RA 
and 
AD=325 
ICD-9 for 
rheumatoid 
arthritis 
(RA) and a 
diagnosis of 
AD made at 
least 120 
days before 
the 
diagnosis of 
RA 
76.5, ≥ 
18 
years 
NK 30 
methotrexate, 
prednisone, 
sulfasalazine, 
three anti-
TNF agents 
(adalimumab, 
etanercept 
and 
infliximab) 
and an anti-
CD20 agent 
(rituximab) 
 
 
 
 
 
 
 
Etanercept- 
subcutaneous
; other drugs-
not stated 
 
Commercia
lly insured 
adults in 
the Verisk 
Health 
claims 
database 
NK NK 
Tobinick  
et al. 
(2006) 
prospe
ctive, 
single-
centre, 
open-
label, 
pilot 
study 
15 
NINCDS-
ADRDA 
Criteria for 
probable 
AD and 
DSM-IV 
criteria for 
AD 
76.7, 
52-94 
18.2 40 Etanercept 
 
 
 
 
 
 
 
 
perispinal 
Community 
25-
50mg 
once 
weekly 
6 
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Appendix C: Inclusion and exclusion criteria for human studies. 750 
 751 
Note: AD=Alzheimer’s Disease, ICD-9= The International Classification of Diseases, MMSE=The Mini–Mental State Examination; Ninth 752 
Revision; RA=rheumatoid arthritis TNF-α=Tumour Necrosis Factor- α; 753 
 754 
  Inclusion criteria Exclusion criteria 
Butchart et al. (2015) 
Modified Hachinski Ischemic Scale score <5 
points, have a standardized MMSE* score 
above 10 and below 27 points, have an 
informant spending at least 24 hours per 
week with the participant, and be capable of 
giving informed consent. Patients taking a 
cholinesterase inhibitor, Memantine, or 
antidepressant medication were required to 
have been on medication for a minimum 
period of 90 days before baseline. 
Prior exposure to amyloid vaccines, monoclonal antibodies, or IV 
immunoglobulins for the treatment of AD*. Also patients with rheumatoid 
arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis, or those 
taking anti–TNF-α agents, immunosuppressive drugs, and/or oral 
prednisone>10 mg/d within the past 90 days. Also participants with 
known contraindications (active infections) or cautions (previous 
significant exposure to tuberculosis, herpes zoster, hepatitis B, heart 
failure, demyelination disorders, and active malignancy 
within past 5 years to the use of etanercept. 
Chou et al. (2016) 
A diagnosis of RA* based on at least two 
outpatient claims with the same diagnosis or 
one inpatient claim as defined by ICD-9* for 
RA and a new diagnosis of AD made at least 
120 days after the initial diagnosis of RA 
Identifiable diagnosis of RA prior to the analysis period, claims data 
about RA for 6 months prior to the analysis period. During any time of 
the analysis period, they also had a diagnosis of inflammatory bowel 
disease (Crohn’s disease and ulcerative colitis), psoriatic arthritis, 
frontotemporal dementia, Lewy body dementia, Parkinson’s disease, 
stroke, or vascular dementia, if they had a diagnosis of AD made before 
the index date (i.e., diagnosis of RA) or less than 120 days after the 
index date. If less than 12 months of data were available for assessment 
of exposure to different therapeutic agents after the index date 
Tobinick et al. (2006) 
Patients with a clinical diagnosis of AD 
declining despite the clinical treatment 
Active infection, multiple sclerosis (or any other demyelinating disorder), 
vascular dementia, clinically significant neurologic disease other than AD 
or a score greater than 4 on the modified Hachinski Ischemic Rating 
Scale, pregnancy, uncontrolled diabetes mellitus, tuberculosis, history of 
lymphoma, or congestive heart failure. Female participants who were 
premenopausal, fertile, or not on acceptable birth control; and patients 
with a white blood cell count < 2500 cells/mm3, hematocrit < 30, or a 
platelet count < 100,000 cells/mm3. Study eligibility also required the 
dose of all central nervous system-active medications to be unchanged 
in the 4 weeks before study initiation and during the entire course of the 
clinical trial. 
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Appendix D: Methodological quality of animal studies.
 
Study 
Random 
allocation of 
treatment 
Blinding 
Inclusion and 
exclusion 
criteria stated 
Sample size 
calculation 
Compliance with 
animal welfare 
requirements 
Conflict of 
interest 
disclosed 
Statistical model 
explained 
Animals with 
comorbidity 
Test animal 
details 
Dose-response 
model 
Every animal 
accounted for 
Optimal time 
window used 
Cavanagh et 
al. (2016) 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate Adequate 
Partially 
adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Detrait et al. 
(2014) 
Adequate Adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate Adequate  Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Gabbita et 
al. (2012) 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
He et al. 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Kim et al. 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
McAlpine et 
al. (2009) 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Medeiros et 
al. 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Medeiros et 
al 2010. 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Montgomery 
et al. (2011) 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Roerink et 
al. (2015) 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate  Adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Adequate 
Russo et al. 
(2012) 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Shi et al. 
(2011) 
Adequate Adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate Adequate 
Partially 
adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Tweedie et 
al. (2012) 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Adequate 
Inadequate/ 
unreported 
Partially 
adequate 
Inadequate/ 
unreported 
Inadequate/ 
unreported 
Adequate 
 Appendix E: Methodological quality of human studies. 
 
 
  
 
Selection 
bias 
Study 
design 
Confounder Blinding 
Data 
collection 
methods 
Withdrawal
s and drop-
outs 
Intervention 
integrity 
Butchart et al. 
(2015) 
Adequate  
 
Adequate Adequate Adequate Adequate Adequate 
Partially 
Adequate 
Reason 
1. Individuals 
somewhat likely 
to be 
representative 
of the target 
population 
2. 80-100% of 
selected 
individuals 
agreed to 
participate 
1. Study 
design: RCT 
2. Study 
randomised 
3. Method of 
randomisatio
n described 
4. Method of 
randomisatio
n was 
appropriate 
1. There were no 
important inter-
group differences 
prior to the 
intervention 
2. 
1. Outcome 
assessor 
unaware of the 
intervention or 
exposure 
status of 
participants 
2. Participants 
unaware of the 
research 
question 
1. Data 
collection tools 
were valid 
2. No 
information 
regarding the 
reliability of 
data collection 
tools 
1. Withdrawals and 
drop-outs were 
reported in terms of 
numbers and/or 
reasons per group 
2. 80-100% of 
participants 
completed the 
study 
1. 80-100% of 
participants 
received the 
allocated 
intervention or 
exposure of interest 
2 Consistency of 
intervention was 
not measured 
3. Unlikely that 
subjects received 
an unintended 
intervention 
Chou et al. 
(2016) 
Partially 
Adequate 
Partially 
Adequate 
Inadequate or 
unclear 
Partially 
Adequate 
Adequate 
Partially 
Adequate 
Adequate 
Reason 
1.  Individuals 
somewhat likely 
to be 
representative 
of the target 
population 
2. 
Retrospective 
study 
1. Study 
design: case- 
control  
2. Study not 
randomised 
 
1. No information 
regarding inter-
group differences 
2. No information 
regarding the 
control of relevant 
confounders 
1. No 
information 
regarding the 
assessors 
2. Participants 
unaware of the 
research 
question 
1. Data 
collection 
methods were 
valid 
2. Data 
collection 
methods were 
reliable 
Cannot comment 
on withdrawals and 
drop-outs due to 
the retrospective 
nature of the study 
 
Tobinick et al. 
(2006) 
Partially 
Adequate 
Adequate 
Inadequate or 
unclear 
Partially 
adequate 
Adequate Adequate 
Inadequate or 
unclear 
Reason 
1.  Individuals 
somewhat likely 
to be 
representative 
of the target 
population 
2.. 80-100% of 
selected 
individuals 
agreed to 
participate 
1.Study 
design: 
controlled 
clinical trial 
2. Study not 
randomised 
1. No information 
regarding inter-
group differences 
2. No information 
regarding the 
control of relevant 
confounders 
1. Outcome 
assessor 
unaware of the 
intervention or 
exposure 
status of 
participants 
2. No 
information 
regarding the 
extent of 
information 
given to study 
participants 
1. Data 
collection 
methods were 
valid 
2. Data 
collection 
methods were 
reliable 
1. Withdrawals and 
drop-outs were 
reported in terms of 
numbers and/or 
reasons per group 
2. 80-100% of 
participants 
completed the 
study 
1. 80-100% of 
participants 
received the 
allocated 
intervention or 
exposure of interest 
2 Consistency of 
intervention was 
not measured 
3. No information 
regarding the 
possibility of 
unintended 
interventions 
 Appendix F: Outcomes of animal studies. 
 
Cognition and 
behavior 
Reduction in 
brain tissue mass 
(atrophy) 
Presence of tangles and 
plaques 
Synaptic Function Other findings 
Cavanagh et al. 
(2016) 
Increase in latency in 
all XPro1595-treated 
mice (p<0.001). A 
significantly lower 
latency than untreated 
mice at day 8 (p<0.05) 
Decreased time spent 
in the avoidance task 
in either genotype, 
following treatment 
(p<0.05) 
unreported unreported 
Treatment with 
XPro1595 caused a 
significantly greater 
decrease in mean fEPSP 
slope in slices from 
TgCRND8 mice 
(p<0.001).  
XPro1595 (p< 0.01) 
abolished the increased 
LTP in slices from 
TgCRND8 mice. 
The input-output 
function in 6-month old 
TgCRND8 XPro1595-
treated mice at a 
prodromal age was 
significantly higher than 
saline-treated TgCRND8 
mice (p < 0.05) for the 
same fiber volley sizes 
and not significantly 
different than NTG 
controls 
unreported 
Detrait et al. 
(2014) 
 
Administration of the 
TNFR2:Fc 
counteracted 
amyloid-induced 
decrease in 
alternation 
percentage (p<0.01) 
Method of 
assessment: 
inhibitory avoidance 
Treatment with 
TNFR2:Fc increased 
the retention 
latencies in a dose-
dependent manner. 
At 10mg/kg the 
retention latency was 
increased when 
compared with the 
control group. At 
30mg/kg a complete 
reversal of the deficit 
was observed 
unreported unreported unreported 
Hippocampal TNF-alpha levels 
doubled in mice administered with 
A only (p<0.001). Treatment with 
TNFR2:Fc normalized the levels 
Gabbita et al. 
(2012) 
 
3,6′-dithiothalidomide 
prevents cognitive 
impairment (p<0.05) 
unreported 
No difference in the number 
of 6E10+ positive cells 
between the treated and 
control groups was found 
unreported 
Both Thalidomide and 3,6′-
dithiothalidomide significantly 
inhibited BV2 TNFα production 
p<0.0001 
and reduced LPS-induced brain 
cortical TNFα mRNA and protein 
levels to near control values 
p<.0001 
3,6′-dithiothalidomide treatment 
reduces brain and spleen tumor 
necrosis factor-α levels, p<.05 
3,6′-DT reduces TNF-α in central 
nervous system-infiltrating 
leukocytes, p<.001 
3,6′-dithiothalidomide decreased 
TNF-α in 
myelomonocytic/granulocytic 
cells, p=.0309 
He et al. (2013) unreported unreported 
Thalidomide reduced A 
load (p<.05) 
Significant decrease in 
6E10-positive plaques in the 
neocortex and hippocampus 
following thalidomide 
administration (p<0.01) 
unreported 
Significant decrease in BACE1 
amount with thalidomide 
application (p<0.05), and lower 
BACE1 activity (p<0.05) 
No significant changes of APH-1 
levels, nicastrin and PS-1 with 
thalidomide application (p>0.05) 
 In the Thalidomide-treated 
group the levels of insoluble 
A1-42 and A1-40 were 
reduced by 51% and 83%, 
respectively  
No significant changes in the 
amount of NEP and ODEA 
expression (p>0.05) 
Kim et al. 
(2016) 
Infliximab treatment 
blocked A1–42-
induced impairment 
of recognition 
memory without 
affecting normal 
recognition memory 
(p=0.0113). 
Discrimination ratio 
was also restored 
after infliximab 
(p=0.0014) 
unreported unreported 
ex vivo: Infliximab 
treatment blocked 
A1–42-induced LTD 
impairment (P< 
0.0001) without 
affecting control LTD 
(P = 0.0004) 
in vitro: Infliximab 
treatment blocked 
A1–42-induced LTD 
impairment 
(P=0.0020) without 
affecting control LTD 
(P = 0.0092) 
unreported 
McAlpine et al. 
(2009) 
unreported unreported 
lenti-DN-TNF-transduced 
brains displayed a 
significant (∼60%) reduction 
in accumulation of 
intraneuronal APP-derived 
6E10-immunoreactive 
protein compared to lenti-
GFP transduced (p<.05) 
XENP345 inhibited the 
appearance of 6E10-
positive cells in the 
hippocampus (p<.05) 
Counts in the hilar region of 
the hippocampus revealed 
that administration of 
XENP345 significantly 
reduced the appearance of 
6E10-IR protein in the hilar 
regions of the hippocampus 
of the LPS-treated 3xTgAD 
mice compared to the 
saline-infused animals 
(p<0.05) 
Inhibition of TNF signaling 
with the DN-TNF inhibitor 
XENP345 (p=0.34) or with 
lenti-DN-TNF (p=0.15) had 
no effect on levels of A 
peptides 
 
unreported unreported 
Medeiros et al. 
(2007) 
iNOS inhibitor AG 
improved the 
cognitive deficits 
during training trials, 
p<.0001 and test 
trials p<.0001 on the 
Morris water maze 
unreported unreported 
Prevented the 
synaptic disruption in 
the CA1, p<.01, CA2 
p<.01 but not in the 
CA3 p<.05 and 
parietal cortex (p>.08) 
unreported 
Medeiros et al. 
(2010) 
Treatment with 
NS398 resulted in a 
significant 
improvement of 
spatial learning 
deficits (p<0.05 and 
p<0.01 compared 
with the PBS/vehicle 
treated group, 
p<0.05 and p<0.01 
compared with the 
AB1-50 vehicle 
treated group 
unreported unreported unreported unreported 
Montgomery et 
al. (2011) 
unreported unreported unreported 
3xTg-ADxTNF-RI/RII 
KO mice showed 
significantly smaller 
evoked fEPSPs 
compared with Non-
Tg mice (p= 0.02) 
unreported 
 Roerink et al. 
(2015) 
unreported unreported unreported unreported 
Perispinal injection of 
radioactively labelled cetuximab, 
etanercept and anakira resulted in 
the accumulation of the drugs in 
the brain in only one out of nine 
animals. In that animal, the 
concentration of the drug was less 
than 0.01% of the injected dose 
Russo et al. 
(2012) 
Aβ1-42-induced 
memory deficits are 
abolished by 3,6′-
dithiothalidomide 
treatment, p <.05 
unreported 
3,6′-dithiothalidomide 
treatment attenuates the 
effect of Aβ1-42 injection on 
hippocampal progenitor cell 
proliferation p<.01 
3,6′-DT treatment 
diminishes the effect of Aβ1-
42 –induced inflammation on 
BrdU-cells survival at 4 
weeks, p<.001 
unreported 
3,6′-dithiothalidomide treatment 
decreases microglia activation in 
response to Aβ1-42 – induced 
neuroinflammation p<.001 
Shi et al. (2011) unreported unreported 
Treatment with Infliximab 
resulted in a decreased in 
the amyloid plaques of 
APP/PS1 transgenic mice. 
A reduction in tau 
phosphorylation levels was 
also reported on semi-
quantitative examination 
unreported unreported 
Tweedie et al. 
(2012) 
drug-treated animals 
performed at a level 
similar to control 
mice in the Morris 
Water (p<0.05) 
unreported unreported unreported 
3,6′-DT reduced LPS-induced 
chronic neuroinflammation and 
restores LPS-mediated abnormal 
hippocampal neuronal plasticity 
(p<0.05) 
Note: A= amyloid beta; APH-1=anterior pharynx-defective 1; APP= Amyloid Precursor; BACE1= Beta-secretase 1; DN-TNF= dominant 
negative tumor necrosis factor; fEPSP=field excitatory postsynaptic potential; GFP= green fluorescent protein; iNOS= Inducible nitric 
oxide synthase; LTD= Long-term depression; Protein; LPS= lipopolysaccharide; NEP= neutral endopeptidase; NTG= nontransgenic; 
PS-1= presenilin-1;TNFR2:Fc= tumor necrosis factor receptor 2 fused to a Fc domain (TNFR2:Fc); TNF-RI/RII KO= tumor necrosis 
factor receptor-1 knockout, 
 
  
 Appendix G: Outcomes of human studies. 
 
 
Cognition and Behaviour Other statistically significant findings 
Butchart et al. (2015) 
Observed Cases 
Week 12:  
no significant difference between etanercept and placebo on SMMSE (p=1.0), 
ADAS-cog (p=0.9), BADLS (p=0.8), NPI (p=0.2), CSDD (p=0.9), CGI-I (p=0.6) 
Week 24 
no significant differences on ADAS-cog (p=0.7), CSDD (p=0.4), SMMSE (p=0.07) 
or CGI-I (p=0.3) were seen, but a significant difference on BADLS (p=0.04) and 
NPI (p=0.02) 
ITT-LOCF 
Week 12 
no significant difference between the etanercept and placebo groups  on SMMSE 
(p=0.9), ADAS-cog (p=0.8), BADLS (p=0.8), NPI (p=0.2), CSDD (p=0.9), CGI-I 
(p=0.7) 
Week 24 
no significant difference on SMMSE (p=0.2), ADAS-cog (p=0.5), BADLS (p=0.1), 
NPI (p=0.2), CSDD (p=0.6), CGI-I (p=0.8) 
 
Chou et al. (2016) 
 
Only the anti-TNF agents as a group showed a 
significant reduction in the relative risk of AD 
among RA subjects following treatment 
(p=0.02) 
 
A significant decrease in the relative risk of AD 
in RA subjects following treatment was only 
found in the Etanercept group (p=0.03) 
Tobinick et al. (2006) 
A significant beneficial effect of treatment on the change in MMSE (p<0.001), 
ADAS-Cog (p<0.002), and SIB (p<0.001) from baseline  
Note: AD= Alzheimer’s Disease; ADAS-cog= Alzheimer's Disease Assessment Scale-cognitive subscale; BADLS= The Bristol Activities of Daily Living 
Scale; CGI= The Clinical Global Impressions Scale; (CSDD)=The Cornell Scale for Depression in Dementia; ITT-LOCF= Intent-to-Treat Last Observation 
Carried Forward; SMMSE= Standardized Mini-Mental State Examination; NPI= The Neuropsychiatric Inventory  
 
